Barclays
PTLA

Barclays’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Barclays’s Portfolio PTLA Stock Details PTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-200
Closed -$1K – 6531
2020
Q1 		$1K Buy
+200
New +$2.5K ﹤0.01% 6098
2019
Q4 		– Sell
-200
Closed -$5K – 7096
2019
Q3 		$5K Hold
200
– – ﹤0.01% 6463
2019
Q2 		$5K Buy
+200
New +$6.27K ﹤0.01% 6704
2019
Q1 		– Sell
-22,100
Closed -$431K – 7513
2018
Q4 		$431K Sell
22,100
-3,700
-14% -$76.1K ﹤0.01% 3935
2018
Q3 		$687K Buy
25,800
+25,400
+6,350% +$829K ﹤0.01% 3996
2018
Q2 		$15K Sell
400
-407,400
-100% -$15.6M ﹤0.01% 6359
2018
Q1 		$13.3M Buy
407,800
+406,800
+40,680% +$17.9M 0.01% 1045
2017
Q4 		$49K Buy
1,000
+600
+150% +$30.3K ﹤0.01% 5778
2017
Q3 		$22K Sell
400
-11,000
-96% -$646K ﹤0.01% 5759
2017
Q2 		$640K Buy
11,400
+1,900
+20% +$76.1K ﹤0.01% 3280
2017
Q1 		$372K Buy
+9,500
New +$303K ﹤0.01% 3701

Barclays's PTLA Position: Q3 2020 in Review

Barclays sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q3 2020, closing a stake of 1,306,377 shares — an estimated $23.5M sold.

Barclays first reported a position in PTLA in Q2 2013 and held it in 29 quarters. The position peaked at $23.5M in Q2 2020. 0 funds tracked by Wall St. Rank hold PTLA as of Q3 2020.

  • Barclays reported no remaining Portola Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
  • Barclays sold 1,306,377 Portola Pharmaceuticals, Inc. shares in Q3 2020, an estimated $23.5M.
  • Barclays first reported a position in Portola Pharmaceuticals, Inc. in Q2 2013 and held it in 29 quarters.
  • Barclays's Portola Pharmaceuticals, Inc. position peaked at $23.5M in Q2 2020.
  • 0 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q3 2020.

Based on Barclays's 13F filing for Q3 2020, filed 12 Nov 2020.